Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- Taiho: CTCL Treatment Zolinza Capsules 100 mg
October 3, 2011
- Pain Treatment at Turning Point with Advent of Lyrica
October 3, 2011
- Takeda: Type 2 Diabetes Treatment Liovel LD and HD
October 3, 2011
- GE Drug Makers Will Need Flexibility to Survive Shift to Biosimilars: Mr Matsubara of Office Medisearch
October 3, 2011
- Afinitor Significantly Increased PFS in Women with Advanced Breast Cancer: Novartis
October 3, 2011
- Asahi Kasei Pharma, tella Announce Joint R&D Agreement for Cell Processing Equipment
October 3, 2011
- Maruho Establishes US Subsidiary
October 3, 2011
- Ono: Corebeta for Inj. 12.5 mg for Improving Image Quality in Coronary CT Angiography
October 3, 2011
- Novartis Pharma: COPD Treatment Onbrez Inhalation Capsules
October 3, 2011
- Nesina Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
October 3, 2011
- Toyobo Biologics Partners with Catalent to Strengthen Contract Manufacturing Business
October 3, 2011
- MSD, Hisamitsu to Terminate Copromotion of Fosamac in February 2012
October 3, 2011
- Barclays Raises MTPC’s Target Share Price on Telavic Survey
October 3, 2011
- Support of Gov’t, Industry Essential for Development of RNA-based Drugs: PMRJ Seminar
October 3, 2011
- Pfizer Starts New Online Promotion with MedPeer
September 30, 2011
- MS Pharma Forms Strategic Alliance with Korean Company in Biosimilars
September 30, 2011
- Takeda Files NDA for Hyperlipidemia Treatment TAK-085 in Japan
September 30, 2011
- Imatinib Significantly Improves Walking Distance in Patients with PAH: Novartis
September 30, 2011
- Takeda President Hasegawa Eyes Joint Research with Chinese Companies
September 29, 2011
- Santen to Acquire French Drugmaker, Strengthen R&D
September 29, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…